1
|
Zhao SJ, Yang M, Shu Y, Huang TT, Li CH, Zhu K, Tang HF. [Rhabdomyomatous dysplasia in pulmonary sequestration in children: a clinicopathological analysis of 15 cases]. Zhonghua Bing Li Xue Za Zhi 2024; 53:177-179. [PMID: 38281787 DOI: 10.3760/cma.j.cn112151-20231023-00287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/30/2024]
Affiliation(s)
- S J Zhao
- Department of Pathology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China Department of Pathology, Xinjiang Urumqi First People's Hospital (Urumqi Children's Hospital), Urumqi 830002, China
| | - M Yang
- Department of Pathology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China
| | - Y Shu
- Department of Pathology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China
| | - T T Huang
- Department of Pathology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China
| | - C H Li
- Department of Pathology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China
| | - K Zhu
- Department of Pathology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China
| | - H F Tang
- Department of Pathology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China
| |
Collapse
|
2
|
Chen J, Shi H, Gao W, Li X, Shu Y, Wang Y, Jiang B, Yang J, Wang P. Effect of the staging comprehensive treatment with acupuncture-moxibustion on Bell's facial palsy in the acute stage. Zhongguo Zhen Jiu 2024; 44:51-56. [PMID: 38191159 DOI: 10.13703/j.0255-2930.20230717-k0002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/10/2024]
Abstract
OBJECTIVES To compare the clinical effect on Bell's facial palsy in the acute stage between the staging comprehensive treatment with acupuncture-moxibustion and western medication. METHODS Sixty patients with Bell's facial palsy in the acute stage were randomly divided into an observation group and a control group, with 30 cases in each one. The patients in the control group were administered orally with prednisone acetate tablets and methylcobalamin tablets until the 28th day of illness. In the observation group, the staging comprehensive treatment with acupuncture-moxibustion was adopted. On the affected side, Qianzheng (EX-HN 16), Yifeng (TE 17), Sibai (ST 2), Yangbai (GB 14), Jiache (ST 6), Dicang (ST 4) and Touwei (ST 8), etc. were stimulated. In the acute stage (Day 1 to 7 of illness), the routine acupuncture and the point-toward-point needle insertion were delivered, no any manipulation was exerted at acupoints, and the needles were retained for 30 min. In the subacute stage (Day 8 to 14 of illness), on the base of the treatment as the acute stage, the depth of needle insertion was adjusted at a part of acupoints and the even needling technique was operated by twisting needle. Besides, electroacupuncture (EA) was attached to Qianzheng (EX-HN 16) and Dicang (ST 4), with continuous wave of low intensity and high frequency, 100 Hz, for 20 min. In the recovery stage (Day 15 to 28 of illness), on the base of the treatment as the subacute stage, the heavy stimulation of acupuncture was given, in which, the sticking and lifting needle techniques were delivered after the needles were inserted from Sibai (ST 2) toward Dicang (ST 4), and from Dicang (ST 4) toward Jiache (ST 6), separately; warm needling was operated at Yifeng (TE 17), and EA changed to stimulate the acupoints with the intermittent wave of high intensity and low frequency, 2 Hz, for 30 min. Acupuncture-moxibustion was given once every other day until the end of the 28th day of illness. The level of House-Brackmann facial nerve function rating scale (H-B grade),the score of Sunnybrook facial nerve grading system (Sunnybrook), the score of facial disability index (FDI), the temperature difference in the infrared thermal imaging facial area and electromyogram (EMG) situation of the affected muscle group were observed before and after treatment in the two groups. Using musculoskeletal ultrasound,the facial nerve diameter was detected and the clinical effect was compared between the two groups. RESULTS After treatment, the level of H-B grade, Sunnybrook score, the scores of physical function and social life function in FDI were improved when compared with those before treatment in the patients of either group (P<0.01, P<0.05), and the results of these evaluations in the observation group were better than those of the control group (P<0.05). After treatment, the temperature difference of the frontal area, the eye area, the zygomatic area and the mouth corner was declined in comparison with that before treatment in the two groups (P<0.05), and the temperature difference in each area in the observation group was lower than that of the control group (P<0.05).The root mean square (RMS) of the frontal muscle group, the zygomatic muscle group and the orbicularis muscle group on the affected side increased in comparison with that before treatment in the two groups (P<0.01), and RMS of the observation group was higher than that of the control group (P<0.05) after treatment. Before treatment, the diameter of the facial nerve on the affected side was larger than that on the healthy side (P<0.01), and after treatment, the diameter on the affected side was reduced when compared with that before treatment in the two groups (P<0.01); the diameter of the facial nerve on the affected side in the observation group was smaller than that of the control group (P<0.05), while, the diameter on the affected side was larger when compared with the healthy side in the control group (P<0.05). The total effective rate of the observation group was 93.3% (28/30), higher than that of the control group (83.3% [25/30], P<0.05). CONCLUSIONS The staging comprehensive treatment with acupuncture-moxibustion is clearly effective on Bell's facial palsy in the acute stage, which affirms the effectiveness of acupuncture-moxibustion for the acute stage of Bell's facial palsy in comparison with conventional western medication.
Collapse
Affiliation(s)
- Jiajie Chen
- College of Acupuncture-Moxibustion and Tuina, Anhui University of CM, Hefei 230031, China
| | - Haiping Shi
- Department of Tuina,First Affiliated Hospital of Anhui University of CM
| | - Wanli Gao
- Department of Tuina,First Affiliated Hospital of Anhui University of CM
| | - Xiaowei Li
- Department of Tuina,First Affiliated Hospital of Anhui University of CM
| | - Yuling Shu
- Department of Tuina,First Affiliated Hospital of Anhui University of CM
| | - Yongzhe Wang
- College of Acupuncture-Moxibustion and Tuina, Anhui University of CM, Hefei 230031, China
| | - Binjian Jiang
- College of Acupuncture-Moxibustion and Tuina, Anhui University of CM, Hefei 230031, China
| | - Jun Yang
- Department of Acupuncture-Moxibustion and Rehabilitation, First Affiliated Hospital of Anhui University of CM
| | - Pin Wang
- College of Acupuncture-Moxibustion and Tuina, Anhui University of CM, Hefei 230031, China.
| |
Collapse
|
3
|
Shu Y, Li WD, Hu QY, Xiong DQ. [Research progress on exosomes and exosomal microRNAs in the occurrence and development of diabetic peripheral neuropathy]. Zhonghua Yu Fang Yi Xue Za Zhi 2024; 58:141-147. [PMID: 38228562 DOI: 10.3760/cma.j.cn112150-20230308-00176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 01/18/2024]
Abstract
Diabetic peripheral neuropathy (DPN) is one of the chronic complications of diabetic neuropathy, and also the main cause of chronic wounds and disability. Exosomes and exosomal-microRNAs (miRNAs) are closely related to DPN and participate in the signal transduction and protein expression of the peripheral nervous system by mediating intercellular communication. However, the specific role and mechanism of EVs and exosomal-miRNAs in the occurrence and development of DPN in high-glucose environments are not fully understood. This article reviews the promotion of EVs and exosomal-miRNAs in the occurrence and development of DPN in inhibiting axon growth, promoting inflammatory response, and inducing vascular injury in a high glucose environment.
Collapse
Affiliation(s)
- Y Shu
- Department of Laboratory, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China Department of medical technology, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China
| | - W D Li
- Department of Laboratory, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China Department of medical technology, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China
| | - Q Y Hu
- Department of Laboratory, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China
| | - D Q Xiong
- Department of Laboratory, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China
| |
Collapse
|
4
|
Shu Y, Xiong Y, Song Y, Jin S, Bai X. Positive association between circulating Caveolin-1 and microalbuminuria in overt diabetes mellitus in pregnancy. J Endocrinol Invest 2024; 47:201-212. [PMID: 37358699 DOI: 10.1007/s40618-023-02137-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/03/2022] [Accepted: 06/13/2023] [Indexed: 06/27/2023]
Abstract
AIMS Mounting evidence has shown that caveolin-1 plays a pathological role in the progression of albuminuria. Our study aimed to provide clinical evidence showing whether circulating caveolin-1 levels were associated with microalbuminuria (MAU) in women with overt diabetes mellitus in pregnancy (ODMIP). METHODS A total of 150 pregnant women were enrolled in different groups, including 40 women with ODMIP and MAU (ODMIP + MAU), 40 women with ODMIP, and 70 women without ODMIP (Non-ODMIP). Plasma caveolin-1 levels were determined by ELISA. The presence of caveolin-1 in the human umbilical vein vascular wall was evaluated by immunohistochemical and western blot analysis, respectively. Albumin transcytosis across endothelial cells was measured using an established nonradioactive in vitro approach. RESULTS Significantly increased levels of plasma caveolin-1 were detected in ODMIP + MAU women. The Pearson's correlation analysis revealed a positive correlation between plasma caveolin-1 levels and Hemoglobin A1c (HbA1c %) as well as with MAU in the ODMIP + MAU group. Simultaneously, experimental knockdown or overexpression of caveolin-1 significantly decreased or increased the level of albumin transcytosis across both human and mouse glomerular endothelial cells (GECs), respectively. CONCLUSIONS Our data showed a positive association between plasma caveolin-1 levels and microalbuminuria in ODMIP + MAU.
Collapse
Affiliation(s)
- Y Shu
- Department of Endocrinology, Institute of Geriatric Medicine, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, 39 Lake Road, East Lake Ecological Scenic, Wuhan, 430077, Hubei Province, China
| | - Y Xiong
- Department of Laboratory Medicine, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, 39 Lake Road, East Lake Ecological Scenic, Wuhan, 430077, Hubei Province, China
| | - Y Song
- Department of Endocrinology, Institute of Geriatric Medicine, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, 39 Lake Road, East Lake Ecological Scenic, Wuhan, 430077, Hubei Province, China
| | - S Jin
- Department of Endocrinology, Institute of Geriatric Medicine, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, 39 Lake Road, East Lake Ecological Scenic, Wuhan, 430077, Hubei Province, China.
| | - X Bai
- Department of Laboratory Medicine, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, 39 Lake Road, East Lake Ecological Scenic, Wuhan, 430077, Hubei Province, China.
| |
Collapse
|
5
|
Wang M, Wang DJ, Shu Y, Zhu D, Yu CW, He XY, Zou L. [ BCS1Neonatal growth retardation and lactic acidosis initiated by novel mutation sites in L gene]. Zhonghua Yu Fang Yi Xue Za Zhi 2023; 57:912-917. [PMID: 37357212 DOI: 10.3760/cma.j.cn112150-20220610-00595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/27/2023]
Abstract
This study aims to analyze the clinical characteristics and genetic variations of two cases with developmental delay and lactic acidosis in a family, and to explore the relationship between genetic variations and clinical features. A retrospective analysis was conducted on the clinical characteristics of two siblings with developmental delay and lactic acidosis who were treated at the Neonatal Department of Children's Hospital of Chongqing Medical University in May 2019 and December 2021, respectively. Whole-exome sequencing was used to detect genetic variations in the affected children. Homology modeling of the BCS1L protein was performed to analyze the structural and functional changes of the protein. The correlation between genetic variations and clinical phenotypes was analyzed. The results showed that the main clinical features of the two affected children in this family were manifestations of mitochondrial respiratory chain complex Ⅲ deficiency, including prematurity, developmental delay, respiratory failure, lactic acidosis, cholestasis, liver dysfunction, renal tubular lesions, coagulation dysfunction, anemia, hypoglycemia, hypotonia, and early death. Whole-exome sequencing revealed a novel deletion mutation c.486_488delGGA (p.E163del) and a novel missense mutation c.992C>T (p.T331I) in the BCS1L gene. Structural analysis of the homology modeling showed that the compound heterozygous mutation had a significant impact on protein function. In conclusion, the novel mutation site c.992C>T (p.T331I) in the BCS1L gene is a "likely pathogenic" mutation, and the compound heterozygous mutation is closely related to the phenotype of mitochondrial respiratory chain complex Ⅲ deficiency.
Collapse
Affiliation(s)
- M Wang
- Department of Clinical Molecular Medicine of Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
| | - D J Wang
- Department of Clinical Molecular Medicine of Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
| | - Y Shu
- Department of Clinical Molecular Medicine of Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
| | - D Zhu
- Department of Clinical Molecular Medicine of Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
| | - C W Yu
- Department of Clinical Molecular Medicine of Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
| | - X Y He
- Department of Clinical Molecular Medicine of Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
| | - L Zou
- Department of Clinical Molecular Medicine of Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China Clinical Research Unit of Children's Hospital in Shanghai Jiao Tong University School of Medicine, Institute of Pediatric Infection, Immunity, and Critical Care Medicine,Shanghai Jiao Tong University School of Medicine, Shanghai 200062, China
| |
Collapse
|
6
|
Shu Y, Ma P, Shen H, Gao W, Chen X, Sun J, Xu L. 145P Preliminary results of a phase Ⅱ study of fruquintinib combined with sintilimab and chemotherapy as the first-line treatment in advanced naive EGFR- and ALK-negative non-squamous non-small cell lung cancer (nsq-NSCLC). Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
7
|
Zhao L, Shu Y, Quan S, Dhanasekaran S, Zhang X, Zhang H. Screening and Regulation Mechanism of Key Transcription Factors of Penicillium expansum Infecting Postharvest Pears by ATAC-Seq Analysis. Foods 2022; 11:foods11233855. [PMID: 36496662 PMCID: PMC9738651 DOI: 10.3390/foods11233855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2022] [Revised: 11/23/2022] [Accepted: 11/25/2022] [Indexed: 12/03/2022] Open
Abstract
Transcription factors play a key role in Penicillium expansum infection process. Although the crucial characteristics of some transcription factors of pathogenic fungi have been found, many transcription factors involved in P. expansum infections have not been explored and studied. This study aimed to screen the transcription factors of P. expansum involved in postharvest pear infections by ATAC-seq analysis and to analyze the differentially expressed peak-related genes by GO enrichment and KEGG pathway analysis. Our results found the up-regulation of differentially expressed peak-related genes involved in the MAPK signaling pathway, pentose phosphate pathway, starch and sucrose metabolism, and pentose and glucuronate interconversions. Our study especially confirmed the differential regulation of transcription factors MCM1, Ste12 and gene WSC in the MAPK signaling pathway and PG1, RPE1 in the pentose and glucuronate interconversions pathway. These transcription factors and related genes might play an essential role in pear fruit infection by P. expansum. RT-qPCR validation of twelve expressed peak-related genes in P. expansum showed that the expression levels of these twelve genes were compatible with the ATAC-Seq. Our findings might shed some light on the regulatory molecular networks consisting of transcription factors that engaged in P. expansum invasion and infection of pear fruits.
Collapse
|
8
|
Kato K, Yoon H, Raymond E, Hubner R, Shu Y, Pan Y, Park S, Ping L, Jiang Y, Zhang J, Wu X, Yao Y, Shen L, Kojima T, Lin CY, Wang L, Tao A, Peng Y, Li L, Xu J. 70O Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
9
|
Zhou C, Huang D, Fan Y, Yu X, Liu Y, Shu Y, Ma Z, Wang Z, Cheng Y, Wang J, Hu S, Liu Z, Poddubskaya E, Disel U, Akopov A, Dvorkin M, Wang Y, Li S, Yu C, Rivalland G. EP08.01-014 Tislelizumab versus Docetaxel in Previously Treated Advanced Non-Small Cell Lung Cancer: Final Analysis of RATIONALE-303. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
10
|
Zhou C, Huang D, Fan Y, Yu X, Liu Y, Shu Y, Ma Z, Wang Z, Cheng Y, Wang J, Hu S, Poddubskaya E, Disel U, Akopov A, Dvorkin M, Wang Y, Ghassemifar S, Li S, Rivalland G. 1031P Tislelizumab (TIS) versus docetaxel (TAX) as second- or third-line therapy in previously treated patients (pts) with locally advanced non-small cell lung cancer (NSCLC): Asian versus non-Asian subgroup analysis of the RATIONALE-303 study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
11
|
Ren S, Wang J, Ying J, Mitsudomi T, Lee DH, Wang Z, Chu Q, Mack PC, Cheng Y, Duan J, Fan Y, Han B, Hui Z, Liu A, Liu J, Lu Y, Ma Z, Shi M, Shu Y, Song Q, Song X, Song Y, Wang C, Wang X, Wang Z, Xu Y, Yao Y, Zhang L, Zhao M, Zhu B, Zhang J, Zhou C, Hirsch FR. Corrigendum to 'Consensus for HER2 Alterations Testing in Non-small Cell Lung Cancer': [ESMO Open Volume 7 Issue 1 (2022) 100395]. ESMO Open 2022; 7:100482. [PMID: 35461023 DOI: 10.1016/j.esmoop.2022.100482] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Affiliation(s)
- S Ren
- Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai
| | - J Wang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
| | - J Ying
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - T Mitsudomi
- Department of Surgery, Kindai University Faculty of Medicine, Osaka, Japan
| | - D H Lee
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - Z Wang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
| | - Q Chu
- Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - P C Mack
- Center of Thoracic Oncology/Tisch Cancer Institute and Icahn School of Medicine, Mount Sinai, New York, USA
| | - Y Cheng
- Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun, China
| | - J Duan
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
| | - Y Fan
- Department of Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences/Zhejiang Cancer Hospital, Hangzhou
| | - B Han
- Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai
| | - Z Hui
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
| | - A Liu
- Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang
| | - J Liu
- Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian
| | - Y Lu
- Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu; Huaxi Student Society of Oncology Research, West China School of Medicine, Sichuan University, Chengdu
| | - Z Ma
- Department of Respiratory Medicine, Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou
| | - M Shi
- Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing
| | - Y Shu
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University/Jiangsu Provincial People's Hospital, Nanjing
| | - Q Song
- Cancer Center, Renmin Hospital of Wuhan University, Wuhan
| | - X Song
- Department of Respiration Medicine, Shanxi Provincial Cancer Hospital, Taiyuan
| | - Y Song
- Department of Respiratory Medicine, General Hospital of Eastern Theater Command, Nanjing
| | - C Wang
- Department of Lung Cancer, Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center of Cancer, Tianjin
| | - X Wang
- Department of Oncology, Qilu Hospital of Shandong University, Jinan
| | - Z Wang
- Department of Oncology, Shandong Cancer Hospital and Institute, Jinan
| | - Y Xu
- Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai
| | - Y Yao
- Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
| | - L Zhang
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou
| | - M Zhao
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang
| | - B Zhu
- Department of Oncology, Xinqiao Hospital, The Army Medical University, Chongqing, China
| | - J Zhang
- Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City; Department of Cancer Biology, University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, USA
| | - C Zhou
- Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai.
| | - F R Hirsch
- Center of Thoracic Oncology/Tisch Cancer Institute and Icahn School of Medicine, Mount Sinai, New York, USA
| |
Collapse
|
12
|
Shu Y, Wang R, Ji M, Shi M, Zhang X. 43P Update on long term outcome of a multicentre, prospective, real-world study of camrelizumab in the treatment of patients with advanced lung cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
13
|
Tarasek M, Shu Y, Kang D, Tao S, Gray E, Huston J, Hua Y, Yeo D, Bernstein M, Foo T. Average SAR prediction, validation, and evaluation for a compact MR scanner head-sized RF coil. Magn Reson Imaging 2022; 85:168-176. [PMID: 34666159 PMCID: PMC8631045 DOI: 10.1016/j.mri.2021.10.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2021] [Revised: 09/01/2021] [Accepted: 10/12/2021] [Indexed: 01/03/2023]
Abstract
A recently developed compact 3 T (C3T) MRI scanner with high performance gradients [1, 2] has a dedicated radiofrequency (RF) transmit coil that exposes only the head, neck and a small portion of the upper body region during head-first scanning. Due to the unique coil geometry and patient positioning, the established SAR model used for a conventional whole-body scanner cannot be directly translated to the C3T. Here a specific absorption rate (SAR) estimation and validation framework was developed and used to implement a dedicated and accurate SAR prediction model for the C3T. Two different SAR prediction models for the C3T were defined and evaluated: one based on an anatomically derived exposed mass, and one using a fixed anatomical position located caudally to the RF coil to determine the exposed mass. After coil modeling and virtual human body simulation, the designed SAR prediction model was implemented on the C3T and verified with calorimetry and in vivo scan power monitoring. The fixed-demarcation exposed mass model was selected as appropriate exposed mass region to accurately estimate the SAR deposition in the patient on the C3T.
Collapse
Affiliation(s)
| | - Y. Shu
- Mayo Clinic, Department of Radiology, Rochester MN U.S
| | - D. Kang
- Mayo Clinic, Department of Radiology, Rochester MN U.S
| | - S. Tao
- Mayo Clinic, Department of Radiology, Jacksonville, FL U.S
| | - E. Gray
- Mayo Clinic, Department of Radiology, Rochester MN U.S
| | - J Huston
- Mayo Clinic, Department of Radiology, Rochester MN U.S
| | - Y Hua
- GE Global Research, Niskayuna NY U.S
| | | | | | - T.K. Foo
- GE Global Research, Niskayuna NY U.S
| |
Collapse
|
14
|
Wang J, Wang Z, Wu L, Li B, Cheng Y, Li X, Wang X, Han L, Wu X, Fan Y, Yu Y, Lv D, Shi J, Huang J, Zhou S, Han B, Sun G, Guo Q, Ji Y, Zhu X, Hu S, Zhang W, Wang Q, Jia Y, Wang Z, Song Y, Wu J, Shi M, Li X, Han Z, Liu Y, Yu Z, Liu A, Wang X, Zhou C, Zhong D, Miao L, Zhang Z, Zhao H, Yang J, Wang D, Wang Y, Li Q, Zhang X, Ji M, Yang Z, Cui J, Gao B, Wang B, Liu H, Nie L, He M, Jin S, Gu W, Shu Y, Zhou T, Feng J, Yang X, Huang C, Zhu B, Yao Y, Wang Y, Kang X, Yao S, Keegan P. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.181] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
15
|
Shu Y, Liu Y, Cui J, Chen X, Miao L, Li Y, Zhu X, He J, Chen P, Dai S. P40.01 Maintenance Anlotinib After Induction Therapy With Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Phase 2 Study. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
16
|
Xu RH, Wang F, Cui C, Yao J, Zhang Y, Wang G, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1482] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
17
|
Haq IU, Mehmood Z, Afzal T, Khan N, Ahmed B, Nawsherwan, Ali L, Khan A, Muhammad J, Khan EA, Khan J, Zakki SA, Xu J, Shu Y. Prevalence and determinants of stunting among preschool and school-going children in the flood-affected areas of Pakistan. BRAZ J BIOL 2021; 82:e249971. [PMID: 34259717 DOI: 10.1590/1519-6984.249971] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2021] [Accepted: 05/13/2021] [Indexed: 11/22/2022] Open
Abstract
Stunting is a significant public health problem in low- and middle-income countries. This study assessed the prevalence of stunting and associated risk factors of stunting among preschool and school-going children in flood-affected areas of Pakistan. A cross-sectional study was conducted by visiting 656 households through multi-stage sampling. Respondent's anthropometric measurements, socio-demographic information and sanitation facilities were explored. A logistic regression model was used to determine determinants of stunting, controlling for all possible confounders. The overall prevalence of stunting in children was 40.5%, among children 36.1% boys and 46.3% of girls were stunted. The prevalence of stunting in under-five children was 50.7%. Female children (OR=1.35, 95% CI:0.94-2.0), children aged 13-24 months (OR=6.5, 95% CI: 3.0-13.9), mothers aged 15-24 years (OR=4.4, 95% CI: 2.6-7.2), joint family (OR=2.1, 95% CI: 1.4-3.0) did not have access to improved drinking water (OR=3.3, 95% CI: 1.9-5.9), and the toilet facility (OR=2.8, 95% CI, 1.9-4.3), while the children from district Nowshera (OR=1.7, 95% CI: 0.9-3.2) were significantly (P<0.05) associated in univariate analysis. The regression model revealed that child age, maternal age, family type, quality of water, and toilet facility, were the significant (P<0.05) factors contributing to child stunting in the flood-hit areas. Identification of key factors might be helpful for policymakers in designing comprehensive community-based programs for the reduction of stunting in flood-affected areas. In disasters such as flood, the detrimental consequences of the stunting problem could be even more on children. Evidence-based education and care must be provided to the families in the flood-affected regions to reduce the stunting problem. The determinants of stunting should be targeted by making comprehensive policies regarding proper nutrition, livelihood, clean water, and sanitation facilities in flood-hit regions.
Collapse
Affiliation(s)
- I Ul Haq
- Department of Public Health & Nutrition, The University of Haripur, Haripur, Khyber Pakhtunkhwa, Pakistan
| | - Z Mehmood
- Department of Math's, Stats & Computer Science, The University of Agriculture Peshawar, Pakistan
| | - T Afzal
- Basic Health Unit Rakhi Mounh, Tehsil Koh-e-Suleman, District Health Authority Dera Ghazi Khan, Pakistan
| | - N Khan
- Goat Production Research Station Charbagh Swat, Livestock and Dairy Development Research Department Khyber Pakhtunkhwa, Pakistan
| | - B Ahmed
- School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China
| | - Nawsherwan
- Department of Preventive Medicine, School of Health Sciences, Wuhan University, China
| | - L Ali
- Department of Biological Sciences, National University of Medical Sciences, Rawalpindi, Pakistan
| | - A Khan
- Department of Public Health & Nutrition, The University of Haripur, Haripur, Khyber Pakhtunkhwa, Pakistan
| | - J Muhammad
- Department of Microbiology, The University of Haripur, Haripur, Khyber Pakhtunkhwa, Pakistan
| | - E A Khan
- Institute of Nursing Sciences, Khyber Medical University, Peshawar, Pakistan
| | - J Khan
- Department of Agriculture, University of Swabi, Khyber Pakhtunkhwa, Pakistan
| | - S A Zakki
- Department of Public Health & Nutrition, The University of Haripur, Haripur, Khyber Pakhtunkhwa, Pakistan
| | - J Xu
- Department of Clinical Nutrition, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
| | - Y Shu
- Department of Clinical Nutrition, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
| |
Collapse
|
18
|
Qiu L, Jin J, Cen H, Zhou K, Xu X, Li F, Wu T, Yang H, Wang Z, Li Z, Bao H, Xu Z, Shu Y. A PHASE I
B
STUDY OF AN ORAL PI3Kδ INHIBITOR LINPERLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T CELL LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.128_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- L. Qiu
- Blood Institute of the Chinese Academy of Medical Sciences lymphoma treatment center Tianjin China
| | - J. Jin
- First Hospital Affiliated Zhe Jiang Medical University Department of Hematology Hangzhou China
| | - H. Cen
- Guangxi Medical University Affiliated Tumor Hospital Department of Medical Oncology Nanning China
| | - K. Zhou
- Henan Cancer Hospital Department of Hematology Zhengzhou China
| | - X. Xu
- Cancer Hospital affiliated to Nantong University Department of Hematology and Lymphoma Nantong China
| | - F. Li
- The First Affiliated Hospital of Nanchang University Department of Hematology Nanchang China
| | - T. Wu
- Guizhou Cancer Hospital Department of Lymphoma Guiyang China
| | - H. Yang
- Cancer Hospital of The University of Chinese Academy of Sciences Department of Lymphoma Hangzhou China
| | - Z. Wang
- Linyi Cancer Hospital Department of Medical Oncology Linyi China
| | - Z. Li
- Sun Yat‐Sen University Cancer Center Department of Medical Oncology Guangzhou China
| | - H. Bao
- Shanghai Yingli Pharmaceutical Co., Ltd Clinical Management Department Shanghai China
| | - Z. Xu
- Shanghai Yingli Pharmaceutical Co., Ltd Clinical Management Department Shanghai China
| | - Y. Shu
- Shanghai Yingli Pharmaceutical Co., Ltd Clinical Management Department Shanghai China
| |
Collapse
|
19
|
Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Wu F, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Jin F, Gao H, An G, Ding C, Jiang X, Xiong J, Zhou X, Hu S, Lu P, Liu A, Guo S, Huang J, Zhu C, Zhao J, Gao B, Chen Y, Hu C, Zhang J, Zhang H, Zhao H, Zhou Y, Tai Y. P79.02 Updated OS and Time to Second Progression with First-Line Camrelizumab Plus Chemo vs Chemo for Advanced Non-Squamous NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
20
|
Jin W, Shu Y, Wang X, Lu S, Shi H. MicroRNA 198 Inhibits Invasion and Metastasis in Non-Small Cell Lung Cancer by Targeting Toll-Like Receptor 4. Indian J Pharm Sci 2021. [DOI: 10.36468/pharmaceutical-sciences.827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
21
|
Wang Z, Zhao J, Ma Z, Cui J, Shu Y, Liu Z, Cheng Y, Leaw S, Wu Y, Ma Y, Tan W, Wang J. 66P Tislelizumab plus chemotherapy as first-line treatment for lung cancer in Chinese patients. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
22
|
Shu Y, Guo J, Ma X, Yan Y, Wang Y, Chen C, Sun X, Wang H, Yin J, Long Y, Yan X, Lu Z, Petersen F, Yu X, Qiu W. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is associated with IRF7, BANK1 and TBX21 polymorphisms in two populations. Eur J Neurol 2020; 28:595-601. [PMID: 33065758 DOI: 10.1111/ene.14596] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2020] [Revised: 10/09/2020] [Accepted: 10/10/2020] [Indexed: 12/20/2022]
Abstract
BACKGROUND AND PURPOSE Autoantibodies targeting the GluN1(NR1) subunit of the anti-N-methyl-D-aspartate receptor (NMDAR) cause encephalitis. Although it has been shown that anti-NMDAR encephalitis is associated with human leukocyte antigen (HLA) loci, susceptibility genes for the disease outside the HLA loci remain unidentified. In this study, we aimed to explore the association of anti-NMDAR encephalitis with non-HLA genes. METHODS Two Chinese anti-NMDAR encephalitis cohorts from Han populations were recruited for this study. The North Chinese case-control set consisted of 98 patients and 460 controls, while the South Chinese case-control set included 78 patients and 541 controls. All participants were genotyped for 28 single nucleotide polymorphisms that are associated with autoimmune disorders or infectious diseases. RESULTS In two independent case-control sets, we identified significant associations of anti-NMDAR encephalitis with IRF7 rs1131665 (odds ratio [OR] 3.34, 95% confidence interval [CI] 1.99-5.63; P < 0.000001, Padjusted = 0.00004), BANK1 rs4522865 (OR 1.44, 95% CI 1.15-1.82; P = 0.0017, Padjusted = 0.0149), and TBX21 rs17244587 (OR 2.03, 95% CI 1.35-3.05; P = 0.00051, Padjusted = 0.0066). Furthermore, analysis of the three polymorphisms with clinical features of the disease revealed that the IRF7 rs1131665 was associated with tumor status. CONCLUSION The present study has for the first time identified non-HLA susceptibility genes for anti-NMDAR encephalitis. The association of IRF7, BANK1 and TBX21 with anti-NMDAR encephalitis suggests that B-cell activation, Th1 responses, virus infection and the type I interferon signaling pathway are involved in the pathogenesis of the disease.
Collapse
Affiliation(s)
- Y Shu
- Department of Neurology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.,Priority Area Asthma and Allergy, Research Center Borstel, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Borstel, Germany
| | - J Guo
- Department of Neurology, Tangdu Hospital of Fourth Military Medical University, Xi'an, China
| | - X Ma
- Department of Neurology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - Y Yan
- College of Life Sciences, Shaanxi Normal University, Xi'an, China
| | - Y Wang
- Department of Neurology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - C Chen
- Department of Neurology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - X Sun
- Department of Neurology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - H Wang
- Department of Neurology, Southern Medical University, Guangzhou, China
| | - J Yin
- Priority Area Asthma and Allergy, Research Center Borstel, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Borstel, Germany
| | - Y Long
- Department of Neurology, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
| | - X Yan
- Department of Neurology, Tangdu Hospital of Fourth Military Medical University, Xi'an, China
| | - Z Lu
- Department of Neurology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - F Petersen
- Priority Area Asthma and Allergy, Research Center Borstel, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Borstel, Germany
| | - X Yu
- Priority Area Asthma and Allergy, Research Center Borstel, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Borstel, Germany
| | - W Qiu
- Department of Neurology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| |
Collapse
|
23
|
Qin S, Li J, Bai Y, Shu Y, Li W, Yin X, Cheng Y, Sun G, Deng Y, Zhong H, Li Y, Qian X, Zhang L, Zhang J, Chen K, Zhang L, Li W, Jiang W, Liu S, Chai K. 104P Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
24
|
Shi M, Gu A, Tu H, Huang C, Wang H, Yu Z, Wang X, Cao L, Shu Y, Wang H, Yang R, Li X, Chang J, Hu Y, Shen P, Hu Y, Guo Z, Tao M, Zhang Y, Liu X, Sun Q, Zhang X, Jiang Z, Zhao J, Chen F, Yu H, Zhang W, Sun J, Li D, Zhou J, Han B, Wu YL. Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial. Ann Oncol 2020; 32:85-96. [PMID: 33130217 DOI: 10.1016/j.annonc.2020.10.479] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2020] [Revised: 09/25/2020] [Accepted: 10/15/2020] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Polymeric micellar paclitaxel (pm-Pac) is a novel Cremophor EL-free, nanoparticle micellar formulation of paclitaxel. We aimed to compare the efficacy and safety between pm-Pac plus cisplatin and solvent-based paclitaxel (sb-Pac) plus cisplatin in advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS A total of 448 stage IIIB to IV NSCLC patients were randomly assigned (2:1) to receive six 3-week cycles of either pm-Pac (230 mg/m2) plus cisplatin (70 mg/m2; n = 300), followed by dose escalation of pm-Pac to 300 mg/m2 from the second 3-week cycle if prespecified toxic effects were not observed after the first cycle, or sb-Pac (175 mg/m2) plus cisplatin (70 mg/m2; n = 148). The primary end point was objective response rate (ORR) assessed by independent review committees (IRCs). The secondary end points included IRC-assessed progression-free survival (PFS), overall survival (OS), and safety. RESULTS Patients in the pm-Pac-plus-cisplatin group showed significant improvements in IRC-assessed ORR compared with those in the sb-Pac-plus-cisplatin group (50% versus 26%; rate ratio 1.91; P < 0.0001). Additionally, subgroup analysis showed that a higher ORR was consistently observed in both squamous and nonsquamous histological types. IRC-assessed median PFS was significantly higher in the pm-Pac-plus-cisplatin group than in the sb-Pac-plus-cisplatin group (6.4-month versus 5.3-month; hazard ratio 0.63; P = 0.0001). Median OS was not significantly different between the two groups. The incidence of treatment-related serious adverse events (9% versus 18%; P = 0.0090) was significantly lower in the pm-Pac-plus-cisplatin group than in the sb-Pac-plus-cisplatin group. CONCLUSION Pm-Pac plus cisplatin yielded superior ORR and PFS along with a favorable safety profile and should become an option for patients with advanced NSCLC. CLINICAL TRIAL IDENTIFIER ClinicalTrials.gov NCT02667743; https://clinicaltrials.gov/ct2/show/NCT02667743.
Collapse
Affiliation(s)
- M Shi
- Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
| | - A Gu
- Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
| | - H Tu
- Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China
| | - C Huang
- Department of Thoracic Oncology, Fujian Cancer Hospital, The Affiliated Cancer Hospital of Fujian Medical University, Fuzhou, China
| | - H Wang
- Department of Medical Oncology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
| | - Z Yu
- Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - X Wang
- Department of Chemotherapy, Qilu Hospital of Shandong University, Jinan, China
| | - L Cao
- Department of Pneumology, Anhui Provincial Hospital, The First Affiliated Hospital of USTC, Hefei, China
| | - Y Shu
- Department of Oncology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China
| | - H Wang
- Department of Medical Oncology, Tianjin Union Medical Centre, Tianjin, China
| | - R Yang
- Department of Tumor Chemotherapy, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Center, Kunming, China
| | - X Li
- Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - J Chang
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
| | - Y Hu
- Department of Medical Oncology, Hubei Cancer Hospital, Wuhan, China
| | - P Shen
- Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China
| | - Y Hu
- Department of Medical Oncology, Chinese PLA General Hospital, Beijing, China
| | - Z Guo
- Department of Pneumology, Shanghai East Hospital, The Affiliated East Hospital of Tongji University, Shanghai, China
| | - M Tao
- Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Y Zhang
- Department of Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou, China
| | - X Liu
- Department of Medical Oncology, Shantou Central Hospital, Affiliated Shantou Hospital of Sun Yat-Sen University, Shantou, China
| | - Q Sun
- Department of Medical Oncology, Henan Provincial Chest Hospital, Zhengzhou, China
| | - X Zhang
- Department of Pneumology, The Affiliated Zhongshan Hospital of Fudan University, Shanghai, China
| | - Z Jiang
- Department of Medical Oncology, Puyang Oilfield General Hospital, Puyang, China
| | - J Zhao
- Department of Medical Oncology, The Affiliated Hospital of Qinghai University, Xining, China
| | - F Chen
- School of Public Health, Nanjing Medical University, Nanjing, China
| | - H Yu
- School of Public Health, Nanjing Medical University, Nanjing, China
| | - W Zhang
- Shanghai Yizhong Biotechnical Co., Ltd., Shanghai, China
| | - J Sun
- Shanghai Yizhong Biotechnical Co., Ltd., Shanghai, China
| | - D Li
- Shanghai Yizhong Biotechnical Co., Ltd., Shanghai, China
| | - J Zhou
- Shanghai Yizhong Biotechnical Co., Ltd., Shanghai, China
| | - B Han
- Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
| | - Y L Wu
- Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
| |
Collapse
|
25
|
Zhao N, Zhou ZL, Wu L, Zhang XD, Han SB, Bao HJ, Shu Y, Shu XG. An update on the status of COVID-19: a comprehensive review. Eur Rev Med Pharmacol Sci 2020; 24:4597-4606. [PMID: 32374000 DOI: 10.26355/eurrev_202004_21046] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The last two decades have witnessed two large-scale pandemics caused by coronaviruses, including severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS). At the end of 2019, another novel coronavirus, designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), hit Wuhan, a city in the center of China, and subsequently spread rapidly to the whole world. Latest reports revealed that more than 800 thousand people in over 200 countries are involved in the epidemic disease by SARS-CoV-2. Due to the high mortality rate and the lack of optimum therapeutics, it is crucial to understand the biological characteristics of the virus and its possible pathogenesis to respond to the SARS-CoV-2. Rapid diagnostics and effective therapeutics are also important interventions for the management of infection control. However, the rapid evolution of SARS-CoV-2 exerted tremendous challenges on its diagnostics and therapeutics. Therefore, there is an urgent need to summarize the existing research results to guide decision-making on the prioritization of resources for research and development. In this review, we focus on our current understanding of epidemiology, pathogenesis, diagnostics and therapeutics of coronavirus disease 2019 (COVID-19).
Collapse
Affiliation(s)
- N Zhao
- Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Liu X, He X, Chen Z, Du S, Yang Y, Shu Y, Li G, Hu Y, Tong R, Li G, Qian Q. SAT-186 Extra-potassium Load from Commonly Used Traditional Chinese Medicines Was an Urgent Problem for CKD Patients. Kidney Int Rep 2020. [DOI: 10.1016/j.ekir.2020.02.198] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
27
|
Jabaji R, Shu Y, Feng M, Feng M, Mirheydar H. 109 Predictors of Rapid Disease Progression from Initial Diagnosis of Erectile Dysfunction to Surgical Intervention. J Sex Med 2020. [DOI: 10.1016/j.jsxm.2019.11.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
28
|
Shu Y, Luo QL, Zhao XP, Ouyang YJ, Su SP. Preparation and Properties of Functionalized Lignin-Modified Polyvinyl Alcohol. INT POLYM PROC 2019. [DOI: 10.3139/217.3841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
AbstractA functional lignin-modified polyvinyl alcohol material was prepared by in-situ copolymerization and alcoholysis of vinyl acetate and functional lignin. We then investigated the molecular functional groups, mechanical properties, thermal properties and flame retardancy of the materials by using Fourier-transform infrared spectrometer, universal testing machine, differential scanning calorimeter, thermal gravimetric analyzer, scanning electron microscope, limiting oxygen indexer and horizontal vertical burning tester. The results show that with increase in functional lignin content, the limiting oxygen index, combustion grade and glass transition temperature of the functional lignin-modified polyvinyl alcohol film increased. Both tensile strength and elongation at break increased first and then decreased with increasing functional lignin content. When the functional lignin content was 15 %, these two indices reached their maximum values. As the functional lignin content increased, the melting temperature of the material gradually rose after a sudden drop. When the functional lignin content was 5 %, the melting temperature was the lowest.
Collapse
Affiliation(s)
- Y. Shu
- 1Key Lab for Fine Processing of Resources and Advanced Materials of Hunan Province, Hunan Normal University, Changsha, PRC
- 2Hunan Engineering Laboratory for Preparation Technology of Polyvinyl Alcohol Fiber Material, Huaihua University, Huaihua, PRC
- 3National and Local Joint Engineering Laboratory for New Petro-Chemical Materials and Fine Utilization of Resources, Hunan Normal University, Changsha, PRC
| | - Q.-L. Luo
- 1Key Lab for Fine Processing of Resources and Advanced Materials of Hunan Province, Hunan Normal University, Changsha, PRC
- 2Hunan Engineering Laboratory for Preparation Technology of Polyvinyl Alcohol Fiber Material, Huaihua University, Huaihua, PRC
| | - X.-P. Zhao
- 1Key Lab for Fine Processing of Resources and Advanced Materials of Hunan Province, Hunan Normal University, Changsha, PRC
- 3National and Local Joint Engineering Laboratory for New Petro-Chemical Materials and Fine Utilization of Resources, Hunan Normal University, Changsha, PRC
| | - Y.-J. Ouyang
- 3National and Local Joint Engineering Laboratory for New Petro-Chemical Materials and Fine Utilization of Resources, Hunan Normal University, Changsha, PRC
| | - S.-P. Su
- 1Key Lab for Fine Processing of Resources and Advanced Materials of Hunan Province, Hunan Normal University, Changsha, PRC
- 3National and Local Joint Engineering Laboratory for New Petro-Chemical Materials and Fine Utilization of Resources, Hunan Normal University, Changsha, PRC
| |
Collapse
|
29
|
Shi Y, Fang J, Shu Y, Wang D, Yu H, Zhao Y, Zhang L, Zhu B, Li X, Chen G, Shi J, Zheng R, Huang J, Yang S, Long J, Gao W, Greco M, Hu G, Li X. OA01.08 A Phase I Study to Evaluate Safety and Antitumor Activity of BPI-7711 in EGFRM+/T790M+ Advanced or Recurrent NSCLC Patients. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.022] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
30
|
Shi Y, Fang J, Shu Y, Wang D, Yu H, Zhao Y, Zhang L, Zhu B, Li X, Chen G, Shi J, Zheng R, Huang J, Yang S, Long J, Gao W, Greco M, Hu G, Li X. A phase I study to evaluate safety and efficacy of BPI-7711 in EGFRm+/T790M+ advanced or recurrent NSCLC patients. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Cheng R, Zhang H, Zong W, Tang J, Han X, Zhang L, Zhang X, Gu H, Shu Y, Peng G, Huang L, Liu Q, Gao X, Guo Y, Yao Z. Development and validation of new diagnostic criteria for atopic dermatitis in children of China. J Eur Acad Dermatol Venereol 2019; 34:542-548. [PMID: 31568595 DOI: 10.1111/jdv.15979] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2019] [Accepted: 09/05/2019] [Indexed: 11/30/2022]
Affiliation(s)
- R. Cheng
- Department of Dermatology Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China
- Institute of Dermatology Shanghai Jiao Tong University School of Medicine Shanghai China
| | - H. Zhang
- Department of Dermatology Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China
- Institute of Dermatology Shanghai Jiao Tong University School of Medicine Shanghai China
| | - W. Zong
- Institute of Dermatology Chinese Academy of Medical Sciences and Peking Union Medical College Nanjing Jiangsu China
| | - J. Tang
- Department of Dermatology Hunan Children's Hospital Changsha Hunan China
| | - X. Han
- Department of Dermatology Shengjing Hospital of China Medical University Shenyang Liaoning China
| | - L. Zhang
- Department of Dermatology China Medical University First Hospital Shenyang Liaoning China
| | - X. Zhang
- Department of Dermatology Children's Hospital of Shanxi Taiyuan Shanxi China
| | - H. Gu
- Institute of Dermatology Chinese Academy of Medical Sciences and Peking Union Medical College Nanjing Jiangsu China
| | - Y. Shu
- Department of Dermatology Hunan Children's Hospital Changsha Hunan China
| | - G. Peng
- Department of Dermatology Shengjing Hospital of China Medical University Shenyang Liaoning China
| | - L. Huang
- Clinical Research Center Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China
- Department of Pediatrics Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China
| | - Q. Liu
- Department of Dermatology Children's Hospital of Shanxi Taiyuan Shanxi China
| | - X. Gao
- Department of Dermatology China Medical University First Hospital Shenyang Liaoning China
| | - Y. Guo
- Department of Dermatology Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China
- Institute of Dermatology Shanghai Jiao Tong University School of Medicine Shanghai China
| | - Z. Yao
- Department of Dermatology Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China
- Institute of Dermatology Shanghai Jiao Tong University School of Medicine Shanghai China
| |
Collapse
|
32
|
Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Jin F, Gao H, An G, Ding C, Jiang X, Xiong J, Zhou X, Hu S, Lu P, Liu A, Guo S, Huang J, Zhu C, Zhao J, Gao B, Chen Y, Hu C, Zhang J, Zhang H, Zhao H, Zhou Y, Tai Y. OA04.03 A Randomized Phase 3 Study of Camrelizumab plus Chemotherapy as 1st Line Therapy for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.425] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
33
|
Zhou Q, Wu YL, Cheng Y, Liu Y, Chen G, Cui J, Yang N, Song Y, Li XL, Lu S, Zhou J, Ma Z, Yu SY, Huang C, Shu Y. CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.002] [Citation(s) in RCA: 43] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
34
|
Xu H, Shu Y, Jian H, Shen J, Xiang J, Li H, Li B, Zhang T, Zhang L, Mao X. P1.14-24 Characterization of Acquired Receptor Tyrosine Kinase Fusions as Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
35
|
Wu Y, Han B, Shi M, Tu H, Gu A, Huang C, Wang H, Yu Z, Wang X, Cao L, Shu Y, Wang H, Yang R, Li X, Chang J, Hu Y, Shen P, Hu Y, Guo Z, Tao M, Zhang Y, Liu X, Sun Q, Zhang X, Jiang Z, Zhao J, Chen F, Sun J, Li D, Zhou J. MA13.11 A Randomized Phase III Study of Cisplatin-Polymeric Micelle Paclitaxel vs Cisplatin-Solvent-Based Paclitaxel in 1st Line Advanced NSCLC. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
36
|
Cheng X, Shu Y, Chen B. A solely ear-involved IgG4-related sclerosing disease with two-years following-up. Eur Ann Otorhinolaryngol Head Neck Dis 2019; 136:401-403. [DOI: 10.1016/j.anorl.2018.02.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2017] [Revised: 02/24/2018] [Accepted: 02/26/2018] [Indexed: 01/13/2023]
|
37
|
Ryan D, Medhekar S, Shu Y, Adams A. Rheumatoid arthritis, osteoporosis screening, and fracture. Ann Epidemiol 2019. [DOI: 10.1016/j.annepidem.2019.06.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
38
|
Yuan CL, Li H, Zhu L, Liu Z, Zhou J, Shu Y. Aberrant expression of long noncoding RNA PVT1 and its diagnostic and prognostic significance in patients with gastric cancer. Neoplasma 2019; 63:442-9. [PMID: 26925791 DOI: 10.4149/314_150825n45] [Citation(s) in RCA: 66] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Emerging evidences indicate that dysregulated long noncoding RNAs (lncRNAs) are implicated in cancer tumorigenesis and progression and might be used as diagnosis and prognosis biomarker, or potential therapeutic targets. LncRNA PVT1 has been reported to be upregulated in diverse human cancers; however, its clinical significance in gastric cancer (GC) remains elusive. This study was to evaluate the expression of PVT1 in GC and further explore its clinical significance.Previous microarray datasets were analyzed to conduct a preliminary screening for candidate lncRNAs of gastric cancer biomarkers in human gastric cancer tissues. Expression levels of PVT1 in 111pairs of gastric cancer and adjacent normal tissues, gastric cancer cell lines and gastric cancer juices compared to their corresponding controls were detected by real-time quantitative RT-PCR assay. A receiver operating characteristic (ROC) curve and Kaplan-Meier analysis were constructed to evaluate the diagnostic and prognostic values. Univariate and multivariate analysis were performed using the Cox proportional hazard analysis.PVT1 expression was remarkably increased in gastric cancer tissues and cell lines compared with that in the normal control, and its up-regulation was significantly correlated to invasion depth (P < 0.001), advanced TNM stage (P = 0.002) and regional lymph nodes metastasis (P < 0.001) in gastric cancer. PVT1 levels were robust in differentiating gastric cancer tissues from controls [area under the curve (AUC) = 0.728; 95 % confidence interval (CI) = 0.665-0.786, p<0.01]. Kaplan-Meier analysis demonstrated that increased PVT1 expression contributed to poor overall survival (P < 0.01) and disease-free survival (P < 0.01) of patients. A multivariate survival analysis also indicated that PVT1 could be an independent prognostic marker. The levels of PVT1 in gastric juice from gastric patients were significantly higher than those from normal subjects (P = 0.03). PVT1 might serve as a promising biomarker for early detection and prognosis prediction of gastric cancer.
Collapse
|
39
|
Zhang S, Zhou X, Zhou X, Zhang Y, Deng Y, Liao F, Yang M, Xia X, Zhou Y, Yin D, Ojaswi P, Hou Q, Wang L, Zhang D, Xia D, Deng Y, Ding L, Liu H, Yan W, Li M, Ma W, Ma J, Yu Q, Liu B, Yang L, Zhang W, Shu Y, Xu H, Li W. Subtype‐specific inherited predisposition to pemphigus in the Chinese population. Br J Dermatol 2018; 180:828-835. [PMID: 30230522 DOI: 10.1111/bjd.17191] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/07/2018] [Indexed: 02/06/2023]
Affiliation(s)
- S.Y. Zhang
- Department of Dermatovenereology Rare Disease Center West China Hospital Sichuan University No. 37 Guo Xue Xiang Street Chengdu Sichuan China 610041
- Precision Medicine Center State Key Laboratory of Biotherapy Precision Medicine Key Laboratory of Sichuan Province West China Hospital Sichuan University and Collaborative Innovation Center No. 17, Section 3, South Renmin Road Chengdu Sichuan China 610041
| | - X.Y. Zhou
- Precision Medicine Center State Key Laboratory of Biotherapy Precision Medicine Key Laboratory of Sichuan Province West China Hospital Sichuan University and Collaborative Innovation Center No. 17, Section 3, South Renmin Road Chengdu Sichuan China 610041
| | - X.L. Zhou
- Department of Dermatovenereology Rare Disease Center West China Hospital Sichuan University No. 37 Guo Xue Xiang Street Chengdu Sichuan China 610041
| | - Y. Zhang
- Department of Thoracic Oncology Cancer Center State Key Laboratory of Biotherapy West China Hospital Sichuan University Chengdu Sichuan China
| | - Y. Deng
- National Office for Maternal and Child Health Surveillance of China Department of Pediatrics West China Second University Hospital Sichuan University Chengdu Sichuan China
| | - F. Liao
- Precision Medicine Center State Key Laboratory of Biotherapy Precision Medicine Key Laboratory of Sichuan Province West China Hospital Sichuan University and Collaborative Innovation Center No. 17, Section 3, South Renmin Road Chengdu Sichuan China 610041
| | - M. Yang
- Department of Pathology West China Hospital Sichuan University Chengdu Sichuan China
| | - X.Y. Xia
- Precision Medicine Center State Key Laboratory of Biotherapy Precision Medicine Key Laboratory of Sichuan Province West China Hospital Sichuan University and Collaborative Innovation Center No. 17, Section 3, South Renmin Road Chengdu Sichuan China 610041
| | - Y.H. Zhou
- Department of Laboratory Medicine Research Center of Clinical Laboratory Medicine West China Hospital Sichuan University Chengdu Sichuan China
| | - D.D. Yin
- Precision Medicine Center State Key Laboratory of Biotherapy Precision Medicine Key Laboratory of Sichuan Province West China Hospital Sichuan University and Collaborative Innovation Center No. 17, Section 3, South Renmin Road Chengdu Sichuan China 610041
| | - P. Ojaswi
- Department of Dermatovenereology Rare Disease Center West China Hospital Sichuan University No. 37 Guo Xue Xiang Street Chengdu Sichuan China 610041
| | - Q.Q. Hou
- Precision Medicine Center State Key Laboratory of Biotherapy Precision Medicine Key Laboratory of Sichuan Province West China Hospital Sichuan University and Collaborative Innovation Center No. 17, Section 3, South Renmin Road Chengdu Sichuan China 610041
| | - L. Wang
- Department of Dermatovenereology Rare Disease Center West China Hospital Sichuan University No. 37 Guo Xue Xiang Street Chengdu Sichuan China 610041
| | - D.Y. Zhang
- Precision Medicine Center State Key Laboratory of Biotherapy Precision Medicine Key Laboratory of Sichuan Province West China Hospital Sichuan University and Collaborative Innovation Center No. 17, Section 3, South Renmin Road Chengdu Sichuan China 610041
| | - D.M. Xia
- Department of Dermatovenereology Rare Disease Center West China Hospital Sichuan University No. 37 Guo Xue Xiang Street Chengdu Sichuan China 610041
| | - Y.Q. Deng
- Precision Medicine Center State Key Laboratory of Biotherapy Precision Medicine Key Laboratory of Sichuan Province West China Hospital Sichuan University and Collaborative Innovation Center No. 17, Section 3, South Renmin Road Chengdu Sichuan China 610041
| | - L. Ding
- Department of Dermatovenereology Rare Disease Center West China Hospital Sichuan University No. 37 Guo Xue Xiang Street Chengdu Sichuan China 610041
| | - H.J. Liu
- Department of Dermatovenereology Rare Disease Center West China Hospital Sichuan University No. 37 Guo Xue Xiang Street Chengdu Sichuan China 610041
| | - W. Yan
- Department of Dermatovenereology Rare Disease Center West China Hospital Sichuan University No. 37 Guo Xue Xiang Street Chengdu Sichuan China 610041
| | - M.M. Li
- Department of Dermatovenereology Rare Disease Center West China Hospital Sichuan University No. 37 Guo Xue Xiang Street Chengdu Sichuan China 610041
| | - W.T. Ma
- Department of Dermatovenereology Rare Disease Center West China Hospital Sichuan University No. 37 Guo Xue Xiang Street Chengdu Sichuan China 610041
| | - J.J. Ma
- Department of Dermatovenereology Rare Disease Center West China Hospital Sichuan University No. 37 Guo Xue Xiang Street Chengdu Sichuan China 610041
| | - Q. Yu
- Department of Dermatovenereology Rare Disease Center West China Hospital Sichuan University No. 37 Guo Xue Xiang Street Chengdu Sichuan China 610041
| | - B. Liu
- State Key Laboratory of Biotherapy West China Hospital Sichuan University and Collaborative Innovation Center Chengdu Sichuan China
| | - L. Yang
- State Key Laboratory of Biotherapy West China Hospital Sichuan University and Collaborative Innovation Center Chengdu Sichuan China
| | - W. Zhang
- Department of Clinical Pharmacology Hunan Key Laboratory of Pharmacogenetics Xiangya Hospital Central South University Changsha China
| | - Y. Shu
- Precision Medicine Center State Key Laboratory of Biotherapy Precision Medicine Key Laboratory of Sichuan Province West China Hospital Sichuan University and Collaborative Innovation Center No. 17, Section 3, South Renmin Road Chengdu Sichuan China 610041
| | - H. Xu
- Precision Medicine Center State Key Laboratory of Biotherapy Precision Medicine Key Laboratory of Sichuan Province West China Hospital Sichuan University and Collaborative Innovation Center No. 17, Section 3, South Renmin Road Chengdu Sichuan China 610041
- Department of Laboratory Medicine Research Center of Clinical Laboratory Medicine West China Hospital Sichuan University Chengdu Sichuan China
| | - W. Li
- Department of Dermatovenereology Rare Disease Center West China Hospital Sichuan University No. 37 Guo Xue Xiang Street Chengdu Sichuan China 610041
| |
Collapse
|
40
|
Si L, Zhang X, Shu Y, Pan H, Wu D, Liu J, Lou F, Wang X, Wen X, Gu Y, Zhu L, Lan S, Cai X, Zhou Y, Ge J, Li J, Wu H, Guo J. KEYNOTE-151: A phase Ib study of second-line pembrolizumab (Pembro) for Chinese patients (pts) with advanced or metastatic melanoma. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy289.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Xing L, Pan Y, Shi Y, Shu Y, Feng J, Li W, Cao L, Wang L, Gu W, Song Y, Yu J. P1.13-25 Efficacy and Safety of Osimertinib in EGFR T790M-Positive Advanced NSCLC Patients with Brain Metastases (APOLLO Study). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.882] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
42
|
Feng J, Shen B, Jiang H, Wang L, Qian J, Shu Y, Chen P, Mao G, Liu B, Zhang X, Liu C, Wu J, Li X, Cai W, Shen W, Wang Q, He J, Hua D, Zhang Z, Zhang Y. Identification of patients who benefit from apatinib in advanced gastric cancer: Data derived from a real-world study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
43
|
Zhao J, Wang Z, Ma Z, Cui J, Shu Y, Liu Z, Cheng Y, Leaw S, Li J, Xia F, Wang J. P1.04-36 Tislelizumab Combined With Chemotherapy as First-Line Treatment in Chinese Patients With Advanced Lung Cancer. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
44
|
Ma L, Chen X, Xie M, Xu T, Wang S, Zhou J, Shu Y. PO-071 Silencing of circRNA004582 sensitises gastric cancer cells to APATINIB via modulating autophagy by targeting miR-3657 and ATG7. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
45
|
Ma L, Jinrong Q, Yanhong G, Shu Y, Chen X. PO-241 Prognostic factors for operable biliary tract cancer: serum levels of lactate dehydrogenase: a strong association with survival. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
46
|
Tillema JM, Weigand SD, Dayan M, Shu Y, Kantarci OH, Lucchinetti CF, Port JD. Dark Rims: Novel Sequence Enhances Diagnostic Specificity in Multiple Sclerosis. AJNR Am J Neuroradiol 2018; 39:1052-1058. [PMID: 29700044 DOI: 10.3174/ajnr.a5636] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2017] [Accepted: 02/10/2018] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE The 2010 McDonald criteria are designed to sensitively detect MS; however, the low specificity of these criteria can occasionally lead to the misdiagnosis of MS. The purpose of this study was to determine whether a novel double inversion recovery MR imaging technique has the potential to increase the specificity of diagnostic criteria distinguishing MS from non-MS white matter lesions. MATERIALS AND METHODS This was a cross-sectional observational study. MR imaging data were acquired between 2011 and 2016. A novel double inversion recovery sequence that suppresses CSF and GM signal was used (GM-double inversion recovery). We compared WM lesions in a group of patients with multiple sclerosis and in a second group of positive controls with white matter lesions who did not have a diagnosis of MS. The presence of a rim on the GM-double inversion recovery MR imaging sequence was combined with the 2001 and 2010 McDonald disseminated-in-space criteria. Multiple MR imaging markers, including lesion location, size, and the presence of a rim, were compared between groups as well as a quantitative measure of lesion T1 hypointensity. RESULTS MR images from 107 patients with relapsing-remitting MS (median age, 32 years) and 36 positive control (median age, 39 years) subjects were analyzed. No significant differences were found in age and sex. In patients with MS, 1120/3211 lesions (35%) had a rim on GM-double inversion recovery; the positive control group had only 9/893 rim lesions (1%). Rims were associated with a decrease in the lesion T1 ratio. Using the 2010 MR imaging criteria plus the presence of rims on GM-double inversion recovery, we achieved 78% and 97% specificity in subjects with ≥1 and ≥2 rim lesions, respectively. CONCLUSIONS The addition of a novel GM-double inversion recovery technique enhanced specificity for diagnosing MS compared with established MR imaging criteria.
Collapse
Affiliation(s)
- J-M Tillema
- From the Departments of Neurology (J.-M.T., M.D., O.H.K., C.F.L.)
| | | | - M Dayan
- From the Departments of Neurology (J.-M.T., M.D., O.H.K., C.F.L.)
| | - Y Shu
- Radiology (Y.S., J.D.P.), Mayo Clinic, Rochester, Minnesota
| | - O H Kantarci
- From the Departments of Neurology (J.-M.T., M.D., O.H.K., C.F.L.)
| | - C F Lucchinetti
- From the Departments of Neurology (J.-M.T., M.D., O.H.K., C.F.L.)
| | - J D Port
- Radiology (Y.S., J.D.P.), Mayo Clinic, Rochester, Minnesota
| |
Collapse
|
47
|
Shu Y, Ye W, Gu YL, Sun P. Blockade of miR-663b inhibits cell proliferation and induces apoptosis in osteosarcoma via regulating TP73 expression. ACTA ACUST UNITED AC 2018; 119:41-46. [PMID: 29405730 DOI: 10.4149/bll_2018_009] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVE This study aimed to investigate the exact role of miR-663b in osteosarcoma (OS) progression and further explore the underlying molecular mechanisms. MATERIALS AND METHODS The miR-663b expression in human OS cell lines was determined by qRT-PCR, and the results suggested that miR-663b was highly expressed in human OS cells. TargetScan was used to predict the potential targets of miR-663b, and the prediction was confirmed by dual-luciferase reporter assay. To investigate the role of miR-663b in OS, miR-663b was down-regulated in U2OS cells using miR-663b inhibitor. CCK8 and flow cytometry were preformed to investigate the proliferation and apoptosis of U2OS cells. Moreover, qRT-PCR and western blot analysis were performed to measure the mRNA and protein expression. RESULTS We found that miR-663b directly targets TP73 and negatively regulates TP73 expression. MiR-663b inhibitor significantly decreased the proliferation ability of U2OS cells, while the percentage of apoptotic cells was markedly increased. The level of Bcl-2 was notably inhibited by miR-663b inhibitor, while Bax expression was significantly enhanced. Moreover, miR-663b down-regulation promoted p53 and p21 expression in U2OS cells. CONCLUSIONS MiR-663b down-regulation represses proliferation and induces apoptosis in OS by targeting TP73. Therefore, we provide a potential therapeutic target for OS treatment (Fig. 6, Ref. 27).
Collapse
|
48
|
Shu Y, Xiong MQ, Hu K, Dong ML, Hu WH. [Application of three questionnaires in screening obstructive sleep apnea in patients with chronic obstructive pulmonary disease]. Zhonghua Yi Xue Za Zhi 2018; 98:1574-1577. [PMID: 29886647 DOI: 10.3760/cma.j.issn.0376-2491.2018.20.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Objective: To evaluate the clinical value of three questionnaires [Sleep Apnea Clinical Score (SACS), Berlin Questionnaire (BQ), and Epworth Sleepiness Scale (ESS)] in screening obstructive sleep apnea (OSA) in patients with chronic obstructive pulmonary disease (COPD). Methods: A total of 198 patients with COPD were assessed the likelihood of OSA by using the SACS, BQ, ESS, which was confirmed by the overnight polysomnography (PSG). The receiver operating characteristic curve (ROC) and the calculated likelihood ratios were used to compare the values of three scoring systems in predicting OSA in COPD patients. Results: The patients had an average age of (65.5±9.3) years and 92.9% (184 cases) of which were male, 14 cases (7.1%) were female; 27 cases (13.6%) had a high probability of OSA by SACS assessment, 61 cases (30.8%) had a high probability screened by BQ, and 72 (36.4%) had OSA high probability by ESS. The diagnosis of OSA in 75 patients (37.9%) were confirmed by PSG. OSA did not be accurately predicted by ESS screening in patients with COPD, with a ROC curve area under the curve of 0.592 (95% CI: 0.509-0.674, P=0.053). BQ had an area under the ROC curve of 0.706 (95% CI: 0.626-0.779, P<0.001). However, the prediction of SACS was much better, with an area under the ROC curve of 0.810 (95% CI: 0.737-0.871, P<0.001). Conclusion: SACS is superior to BQ and ESS in predicting OSA in this group of patients with COPD.
Collapse
Affiliation(s)
- Y Shu
- Respiratory Department, Renmin Hospital of Wuhan University, Wuhan 430060, China
| | | | | | | | | |
Collapse
|
49
|
Shu Y, Zhang L, Chang Y, Li R, Sun X, Li J, Wu H, Yang Y, Peng L, Lu Z, Kermode AG, Qiu W. Association of serum Cystatin C with neuromyelitis optica spectrum disorders. Eur J Neurol 2018; 25:999-1002. [PMID: 29603501 DOI: 10.1111/ene.13646] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2017] [Accepted: 03/22/2018] [Indexed: 11/29/2022]
Affiliation(s)
- Y. Shu
- Department of Neurology; The Third Affiliated Hospital of Sun Yat-sen University; Guangzhou China
| | - L. Zhang
- Department of Neurology; The Fifth Affiliated Hospital of Sun Yat-sen University; Zhuhai Guangdong China
| | - Y. Chang
- Department of Neurology; The Third Affiliated Hospital of Sun Yat-sen University; Guangzhou China
| | - R. Li
- Department of Neurology; The Third Affiliated Hospital of Sun Yat-sen University; Guangzhou China
| | - X. Sun
- Department of Neurology; The Third Affiliated Hospital of Sun Yat-sen University; Guangzhou China
| | - J. Li
- Department of Neurology; The Third Affiliated Hospital of Sun Yat-sen University; Guangzhou China
| | - H. Wu
- Department of Neurology; The Third Affiliated Hospital of Sun Yat-sen University; Guangzhou China
| | - Y. Yang
- Department of Neurology; The Third Affiliated Hospital of Sun Yat-sen University; Guangzhou China
| | - L. Peng
- Department of Neurology; The Third Affiliated Hospital of Sun Yat-sen University; Guangzhou China
| | - Z. Lu
- Department of Neurology; The Third Affiliated Hospital of Sun Yat-sen University; Guangzhou China
| | - A. G. Kermode
- Department of Neurology; The Third Affiliated Hospital of Sun Yat-sen University; Guangzhou China
- Department of Neurology; Centre for Neuromuscular and Neurological Disorders; Sir Charles Gairdner Hospital; Queen Elizabeth II Medical Centre; University of Western Australia; Perth Australia
| | - W. Qiu
- Department of Neurology; The Third Affiliated Hospital of Sun Yat-sen University; Guangzhou China
| |
Collapse
|
50
|
Shu Y, Chang Y, Wu H, Li J, Cao B, Sun X, Wang J, Peng L, Hu X, Yu X, Qiu W. Serum cystatin C and anti-N-methyl-D-aspartate receptor encephalitis. Acta Neurol Scand 2018; 137:515-522. [PMID: 29315460 DOI: 10.1111/ane.12894] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/14/2017] [Indexed: 12/15/2022]
Abstract
BACKGROUND Cystatin C (CysC) is associated with many neurodegenerative disorders and autoimmune diseases, but its relationship with anti-N-Methyl-D-aspartate receptor (anti-NMDAR) encephalitis is unknown. METHODS Serum levels of CysC were determined in 66 patients with anti-NMDAR encephalitis and 115 healthy controls. Of the 66 patients, 30 had a follow-up evaluation at 3 months after admission. Association of CysC with anti-NMDAR encephalitis and its clinical parameters were evaluated in the patients. RESULTS The serum levels of CysC were significantly lower in patients with anti-NMDAR encephalitis than in controls (0.70 ± 0.13 vs 0.83 ± 0.17 mg/mL, P < .001). Disease severity and disease duration were significantly associated with CysC levels. Furthermore, a follow-up evaluation revealed that after treatment anti-NMDAR encephalitis patients had significantly increased serum CysC levels (P < .001) and significantly decreased modified Rankin Scale (mRS) scores (P < .001) compared with before treatment. In addition, a significant negative correlation was observed between the change in CysC levels and the change in mRS scores (r = -.700, P < .001). CONCLUSION Our results show that the serum levels of CysC are associated with anti-NMDAR encephalitis and its clinical parameters and that the changes in CysC levels correlate with therapeutic effect. Therefore, our findings provide new insights into the association between serum CysC and anti-NMDAR encephalitis.
Collapse
Affiliation(s)
- Y. Shu
- Department of Neurology; The Third Affiliated Hospital of Sun Yat-Sen University; Guangzhou China
| | - Y. Chang
- Department of Neurology; The Third Affiliated Hospital of Sun Yat-Sen University; Guangzhou China
| | - H. Wu
- Department of Neurology; The Third Affiliated Hospital of Sun Yat-Sen University; Guangzhou China
| | - J. Li
- Department of Neurology; The Third Affiliated Hospital of Sun Yat-Sen University; Guangzhou China
| | - B. Cao
- Department of Clinical Laboratory; The Third Affiliated Hospital of Sun Yat-Sen University; Guangzhou China
| | - X. Sun
- Department of Neurology; The Third Affiliated Hospital of Sun Yat-Sen University; Guangzhou China
| | - J. Wang
- Department of Gynecology; The Third Affiliated Hospital of Sun Yat-Sen University; Guangzhou China
| | - L. Peng
- Department of Neurology; The Third Affiliated Hospital of Sun Yat-Sen University; Guangzhou China
| | - X. Hu
- Department of Neurology; The Third Affiliated Hospital of Sun Yat-Sen University; Guangzhou China
| | - X. Yu
- Priority Area Asthma and Allergy; Research Center Borstel; Airway Research Center North (ARCN); German Center for Lung Research (DZL); Borstel Germany
| | - W. Qiu
- Department of Neurology; The Third Affiliated Hospital of Sun Yat-Sen University; Guangzhou China
| |
Collapse
|